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Background:  The  long-term  antibody  response  to measles  vaccine  (MV)  administered  at  age 6  months
with  or  without  subsequent  doses  is not  well  documented.
Methods: Measles  serum  antibody  responses  were  evaluated  after  a supplemental  dose  of  measles  vac-
cine (sMV)  administered  at a median  age of 20  months  among  Malawian  children  who  had  previously
received  2  doses  of  measles  vaccine  (MV)  at ages  6  and  9 months  (HIV-infected  and  random  sample  of
HIV-uninfected)  or 1  dose  at age  9 months  (random  sample  of HIV-uninfected).  We compared  measles
antibody  seropositivity  between  groups  by  enzyme  linked  immunoassay  and seroprotection  by plaque
reduction  neutralization  geometric  mean  concentrations.
Results:  Of  1756  children  enrolled,  887  (50.5%)  received  a sMV  dose  following  MV  at 9  months  of  age
and  had specimens  available  after  sMV  receipt,  including  401 HIV-uninfected  children  who  received
one  MV  dose  at 9  months,  464  HIV-uninfected  and  22  HIV-infected  children  who  received  two  doses
of  MV at  ages  6 and  9 months.  Among  HIV-uninfected  children,  protective  levels  of  antibody  were
found  post  sMV  in  90–99%  through  ages  24–36  months  and  were  not  affected  by  MV  schedule.  Geo-
metric  mean  concentration  levels  of measles  antibody  were  signiﬁcantly  increased  post-sMV  among
those  HIV-uninfected  children  previously  non-responsive  to vaccination.  Among  HIV-infected  children,
the  proportion  seroprotected  increased  initially  but  by 9 months  post-sMV  was  no  higher than  pre-sMV.
Conclusions:  Our  ﬁndings  support  early  2-dose  MV  to provide  measles  immunity  for young  infants  without
risk  of  interference  with  antibody  responses  to subsequent  MV doses  administered  as  part  of SIAs.
Published  by  Elsevier  Ltd. This  is  an  open  access  article  under  the CC BY-NC-ND  license  (http://. Background
The World Health Organization (WHO) recommends that chil-
ren be vaccinated with at least two doses of measles vaccine (MV).
n areas of the world with high rates of both HIV and measles infec-
ion, the World Health Organization recommends that a ﬁrst MV
Abbreviations: MV,  measles vaccine; sMV, supplemental measles vaccine; SIA,
upplemental immunization activities; RT-PCR, reverse-transcriptase polymerase
hain reaction; EIA, enzyme immunoassay; PRN, plaque reduction neutralization;
MC, geometric mean concentration.
∗ Correspondence to: MPH, 1600 Clifton Road, NE, Mailstop A-32, Atlanta, GA
0329-4027, USA. Tel.: +1 404 639 4830.
E-mail address: afowlkes@cdc.gov (A.L. Fowlkes).
ttp://dx.doi.org/10.1016/j.vaccine.2016.01.055
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-Ncreativecommons.org/licenses/by-nc-nd/4.0/).
dose may  be offered as early as age 6 months of age, with two
additional doses administered through routine services and/or sup-
plemental immunization activities (SIAs) according to the national
immunization schedule [1]. Strategies to introduce MV  at ages
younger than age 9 months must weigh the potential for a lower
antibody response due to interference of maternal antibodies and
possibly immature immune systems with the risk of develop-
ing measles in the ﬁrst year of life [2,3]. Data on the long-term
antibody response to MV  administered at age 6 months with or
without subsequent doses are inconclusive [4–6]. We  have previ-
ously demonstrated protective levels of antibody more than a year
post-vaccination among HIV-uninfected children in Malawi who
were randomized to receive either one MV dose at age 9 months
or two MV  doses at ages 6 and 9 months [7,8]. However, the two-
dose MV  schedule did not appear to improve protection among
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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IV-infected children beyond that reported by prior studies of vac-
ination of HIV-infected children at 9 months of age [9]. During
he study, a SIA was conducted, which afforded the opportunity to
ompare antibody responses to the supplemental dose of measles
accine (sMV) for the two vaccination strategies.
. Methods
alawi study of measles vaccination in HIV-infected and
uninfected children
The study design and detailed methods have been described
n previous publications [7,8]. Brieﬂy, the study was  conducted
n Blantyre, Malawi from August 2000 through March 2003, at
hich time the HIV infection prevalence among women  of child
earing age was approximately 33% [10]. During the infant’s 14-
eek routine immunization visit at the Ndirande Health Center,
327 children born to HIV-uninfected mothers were enrolled
nd randomized to receive either two doses of standard-titer
dmonston–Zagreb MV  (Berna Biotech) at ages 6 and 9 months
r one dose at age 9 months; all 429 children born to HIV-infected
others were assigned to the 2-dose MV  group. Adverse events
ere assessed 7 and 21 days after receipt of any MV dose. Blood
as drawn and clinical information was collected at enrollment
nd during each follow-up appointment scheduled at ages 6, 9, 12,
0, 24, 30, and 36 months. Clinical information was also obtained
n outpatient clinic visits, hospitalizations, and deaths. Antiretrovi-
al therapy was not available in the public sector at the time of this
tudy. Previous publications reported the detailed methods, clini-
al follow-up, loss to follow-up, and the antibody response to early
nd 9-month MV doses [7,8].
.1. Evaluation of supplemental measles vaccination
In August of 2002, a nationwide measles vaccination SIA for all
hildren ages 9–59 months was conducted by the Malawi Ministry
f Health, in partnership with WHO, and the United Nations Chil-
ren’s Fund. At the time of the SIA, there were no recently reported
easles cases near the study region of Malawi, thus approval was
eceived by the Institutional Review Boards and Ministry of Health
or parents of children in the measles study aged <20 months to
e given the option to defer sMV  until age 20–24 months, the
lanned follow-up age for study children. A revised consent form
as developed for the parents/guardians explaining the option to
efer vaccination in the SIA. Parents/guardians presenting children
or vaccination during the SIA were referred to the study clinic
which was located at a government health center) for sMV  receipt
hen campaign staff recognized the study participation stamp in
he immunization card. Therefore children received sMV  through
he SIA campaign directly, the study clinic during the SIA, or a
ollow up study clinic visit. Parent/guardian report and immuniza-
ion cards were used to document sMV  receipt at the SIA.
.2. Measles antibody and HIV detection
Measles serologic testing by enzyme immunoassay (EIA, Trinity
iotech) and HIV-testing by real-time reverse-transcriptase poly-
erase chain reaction (RT-PCR) were performed at the Centers
or Disease Control and Prevention as described previously [7].
o account for documented reductions in EIA sensitivity in serum
pecimens with lower levels of measles antibody compared with
he gold standard plaque reduction neutralization (PRN) [4], spec-
mens from all HIV-infected children and a random selection of
IV-uninfected children with follow-up through the 12 and 24
onth study visits were also tested for measles antibody by plaque4 (2016) 1459–1464
reduction neutralization (PRN) at the Food and Drug Administra-
tion [8]. Children with specimens randomly selected for PRN testing
were representative of the total study population. We  deﬁned
seropositivity as an immune status ratio >1.1 from the measles EIA
assay and a seroprotective antibody titer as a measles PRN antibody
titer ≥120 mIU/mL relative to WHO  II Reference serum, 66/202 [11].
2.3. Data analysis
In previous publications, children’s data were censored at the
time of sMV  receipt. In the present analysis, we  included children
who had received sMV  >3 months after their routine 9-month MV
dose and had data available from at least one specimen collected
>28 days following sMV  receipt. For each child, we  used the speci-
men  taken on the date of sMV  or the most recent specimen available
prior to sMV  to determine the pre-sMV measles antibody levels.
We categorized post-sMV specimens according to the number of
months since sMV  receipt: <3 months, 3 to <6 months, 6 to <9
months, and >9 months. Seven children who seroconverted to HIV
after age 12 months were analyzed separately.
Among HIV-uninfected children, we compared responses to
sMV  among those who  had previously received 1- or 2- doses of MV.
We also compared responses among HIV-infected and -uninfected
children. For each time point, we calculated the proportion seropos-
itive by EIA and seroprotected by PRN and the geometric mean
concentration (GMC) of the measles neutralizing antibody levels.
The proportion of measles seropositive or seroprotected patients
were compared across study groups at each time point using the
pairwise chi-square comparisons or Fisher’s exact tests at time
points with a small sample size. The log-transformed neutralizing
antibody titers at different time points were compared within and
between study groups using a one way  analysis of variance and
pairwise t-tests to identify speciﬁc group differences. Stata, version
12 (College Station, TX) was used for analysis.
3. Results
Of 1756 children originally enrolled, 1060 (60.4%) children
remained in the study through receipt of the sMV; 887 (83.7%)
had antibody data available after sMV  receipt. Children in all study
groups received sMV  at approximately age 20 months, a median
of 11 months (interquartile range 9.5–14.6) after receipt of the
9-month routine MV  dose (Table 1). The demographic character-
istics of children included in this sMV  evaluation were similar to
the total study population (data not shown) and did not differ
among HIV-uninfected study groups (Table 2) [7]. Due to the selec-
tion of children for the present study based on the availability of
specimen test results following sMV, which occurred during the
children’s ﬁnal year of participation, study attrition and mortality
rates did not differ according to HIV-infection status; however, as
previously reported, HIV-infected children were lost to follow-up in
the full study by age 20 months signiﬁcantly more frequently, with
mortality as the leading cause [8]. Consistent with the evaluation
of primary vaccination, no serious adverse events were identiﬁed
following sMV, and rates of outpatient clinic visits, hospitaliza-
tions, and deaths were similar 30 days before and 30 days after
sMV  for each study group (data not shown). A signiﬁcantly higher
proportion of HIV-uninfected children received sMV  through the
SIA compared with HIV-infected children (29.7% [263/865] vs. 9.1%
[2/22]); however, no differences in antibody response was  detected
according to SIA vs. study clinic sMV.Children without HIV infection
Prior to sMV, approximately 81% of HIV-uninfected 1- and 2-MV
dose recipients were seropositive by EIA, and approximately 89%
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Table  1
Percent of children measles antibody positive by EIA or seroprotected by PRN assays before and after a supplemental dose of measles vaccine (sMV) among children
randomized to receive routine measles vaccination at 9 months (MV 9) or 6 and 9 months (MV  6&9) of age by HIV infection status. No HIV-exposed children were randomized
to  receive MV at 9 months only.
MV  schedule and HIV infection by
measles detection assay type
Measles antibody
detected after primary
MV (pre-sMV)
Measles antibody detected by number of months following supplementary MVa
<3 months 3–6 months 6–9 months >9 monthsb
No./No. (%) p value No./No. (%) p value No./No. (%) p value No./No. (%) p value No./No. (%) p value
Enzyme immunoassay
MV  9 months, HIV-uninfected 327/401 (81.6) REF 22/22 (100) – 219/221 (99.1) REF 139/140 (99.3) REF 96/101 (95.1) REF
MV  6&9 months, HIV-uninfected 374/464 (80.6) NS 41/41 (100) – 256/268 (95.5) <0.05 120/129 (93.0) <0.05 124/132 (93.9) NS
MV  6&9 months, HIV-infected 8/22 (36.4) <0.01 3/3 (100) – 10/15 (66.7) <0.01 2/5 (40.0) <0.01 2/8 (25.0) <0.01
Plaque reduction neutralization
MV  9 months, HIV-uninfected 183/206 (88.8) REF 11/11 (100) – 106/107 (99.1) REF 92/93 (98.9) REF 80/81 (98.8) REF
MV  6&9 months, HIV-uninfected 189/211 (89.6) NS 22/22 (100) – 100/103 (97.1) NS 74/77 (96.1) NS 89/97 (94.7) NS
MV  6&9 months, HIV-infected 8/21 (38.1) <0.01 3/3 (100) – 11/15 (73.3) <0.01 2/5 (40.0) <0.01 2/6 (33.3) <0.01
a The median age at each time of measurement did not differ signiﬁcantly by study group and was observed as the following: 20.1 months pre-sMV, 24.3 months at <3
months post-sMV, 24.2 months at 3-6 months post-sMV, 27.7 months at 6–9 months post-sMV, and 30.3 at >9 months post-sMV.
b The median number of months following sMV  included in the >9 months group was  12.1 months with a range of 9.3–24.6 months and interquartile range of 10.3–15.5
months.
Table 2
Demographic characteristics of children randomized to receive routine measles vaccination at 9 months (MV  9) or 6 and 9 months (MV 6&9) of age by HIV infection status.
MV  9 months, HIV-uninfected
(n  = 401)
MV 6&9 months, HIV-uninfected
(n = 464)
MV 6&9 months, HIV-infected
(n = 22)
No. (%) No. (%) No. (%) p value
Demographics
Male 199 (49.6) 221 (47.6) 14 (63.6) NS
Owns home 139 (34.7) 151 (32.5) 3 (13.6) NS
>4  kids in the home 84 (21.0) 69 (14.9) 1 (4.6) 0.017
Electricity in home 155 (38.7) 196 (42.2) 9 (40.9) NS
Running water in home 22 (5.5) 24 (5.2) 4 (18.2) 0.035
Maternal Education > Primary 126 (31.4) 157 (33.8) 4 (18.2) NS
Paternal Education > Primary 243 (63.0) 291 (65.0) 11 (52.4) NS
Birthweight <3.0 kg 196 (48.9) 213 (45.9) 8 (36.4) NS
Nutritional status at sMVa
Stunted (0.0) (0.0) (0.0) NS
Underweight 87 (21.7) 97 (20.9) 12 (54.5) 0.001
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a The nutritional status z-score cut-off used to deﬁne stunting, underweight and 
ere seroprotected according to PRN testing (Table 1). Both the
ensitivity and speciﬁcity of the EIA relative to the PRN assay were
1% (95% CI: 89.9–92.7% and 89.3%– 93.2%, respectively) [8]. The
re-sMV measles neutralizing antibody GMC  did not differ signiﬁ-
antly according to vaccine schedule (Fig. 1).
At each time point measured after sMV, the proportion of chil-
ren seropositive was signiﬁcantly higher than pre-sMV; most
IV-uninfected children remained both measles seropositive and
eroprotected through the end of the study. The measles anti-
ody GMC  rose sharply after vaccination, showing a 3-fold increase
Fig. 1), but then fell quickly again such that by >9 months post-sMV
he GMCs were only 1.3 and 1.4 times higher than the pre-sMV
alues among 1- and 2-MV dose recipients, respectively. Further
valuation of GMCs according to children’s pre-sMV antibody level
emonstrated that pre-sMV seronegative children maintained a 4-
old or higher GMC  compared with their pre-sMV values through
9 months post-sMV (pre-sMV GMC  range 44–80 mIU/mL vs. >9
onths post-sMV GMC  range 161–742; p < 0.001, Fig. 2). By con-
rast, it was the pre-sMV measles antibody positive children whose
easles antibody level at >9 months post-sMV had fallen to lev-
ls comparable to the pre-sMV values. No signiﬁcant differences in
he measles antibody GMC  between 1- and 2-MV dose groups were
etected at any time point post-sMV.
Prior to sMV, HIV-uninfected females in both the 1- and 2-dose
V  groups had signiﬁcantly higher measles antibody GMCs than6 (1.3) 2 (9.1) NS
g from height-for-age, weight-for-age, and height-for-weight was < −2.0.
males (data not shown); similar ﬁndings were previously reported
[7]. Following sMV, no gender differences were detected at any time
point for any study group. In addition, measles antibody response
to sMV  did not vary according to nutritional status.
3.1. HIV-infected children
Of 45 HIV-infected children remaining in the study at 12
months of age, 28 (62.2%) met  inclusion criteria for the sMV
evaluation. Only 38.1% of HIV-infected children were seropositive
pre-sMV—signiﬁcantly lower (p < 0.001) than other study groups
(Table 1, Fig. 1). Among 15 HIV-infected children with specimens
collected 3–6 months following sMV, a signiﬁcant increase in
the GMC  (270 mIU/mL) and the proportion seropositive and sero-
protected (66.7% and 73.3%, respectively, p < 0.05) was observed.
However, this increase in measles antibody levels was not sus-
tained, as indicated by seropositivity and seroprotection rates at
or below 40% at later time points. The pattern of an initial rise in
GMCs followed by rapid fall post-sMV was similar to that in the
HIV-uninfected groups except that even in those seronegative pre-
sMV, a sustained increase in antibody level was not seen (Fig. 2). The
proportion of HIV-infected children seropositive and seroprotected
did not vary at any time point by nutritional status indicators; how-
ever, the pre-sMV antibody titers were signiﬁcantly lower among
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MEASLES  VACCIN ATI ON GR OUP GMC (95% CI) GMC (95% CI) GMC (95% CI) GMC (95% CI) GMC (95% CI)
MV 9  MONTHS 464.1  (395-545) 1236.5  (620-2490) 897.8  (765-1064) 678.6  (572-812) 601.8  (503-721)
MV 6 &9 MO NTHS , HIV-UNINFECTED 395.4  (347-455) 1286.9  (916-1808) 796.3  (659-953) 584.1  (464-728) 561.2  (469-679)
MV 6 &9 MO NTHS , HIV-INFECTED 69.4 (37 -129) 512.9  (0-6503) 262.4  (130-528) 103.5  (30 -354) 142.6  (32 -633)
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Fig. 1. Geometric mean concentration of measles antibody before and after a supplemental dose of measles vaccine (sMV) among children randomized to receive measles
vaccination (MV) at 9 months or 6 and 9 months of age by HIV infection status. No HIV-exposed children were randomized to receive MV  at 9 months only. The protective
level  of measles antibody (120 mIU/mL) is relative to WHO  II Reference Serum 66/202.
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Fig. 2. Geometric mean concentration of measles antibody before and after a supplemental dose of measles vaccine (sMV) according to measles seropositivity pre-sMV, by
vaccine schedule and HIV infection status.
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nderweight children compared with other weight categories
GMC 76 [95%CI: 4–166] vs. 204 [95% CI: 33–327], p < 0.05).
Among the 7 children excluded from other analyses due to HIV
eroconversion after age 12 months, 5 received sMV  after sero-
onverting to HIV. At the time of sMV, 4 (57.1%) of these children
ere measles positive by EIA, 5 (71.4%) were seroprotected, and
he GMC  was 225.0 mIU/mL. Within six months following sMV, 5
f 6 (83.3%) children were seropositive and 5 (83.3%) children were
eroprotected; however, it was not the same child testing nega-
ive by EIA and PRN. After >9 months following sMV, only 2 of 5
hildren were seropositive by EIA, although three of four with PRN
esults available were still considered seroprotected and the GMC
as 400 mIU/mL.
. Discussion
Among HIV-uninfected children, we observed a sustained
easles antibody response to sMV  among previous MV  non-
esponders that was similar for children who had received either
 routine single MV  dose at age 9 months or an early, 2-dose MV
chedule at ages 6 and 9 months. Consistent with our ﬁndings fol-
owing the 1- and 2-dose MV  receipt, we found after sMV  that when
easured by EIA, measles seropositivity rates were lower among
-dose than 1-dose recipients, but by the gold standard PRN, rates
f seropositivity and seroprotection did not differ signiﬁcantly by
accination schedule [8].
We  were able to utilize the post-sMV period to systematically
valuate the antibody response to sMV. It is reassuring that receipt
f an early MV  dose at age 6 months did not adversely affect
esponses elicited by a routine dose of MV at age 9 months nor
he sMV  given later among HIV-uninfected children. These ﬁndings
re consistent with studies that found no evidence of interference
o sMV  subsequent to an early dose of MV [4,12], and support the
pproach of recent studies that indicate early MV beneﬁts in reduc-
ng infant hospitalization and mortality [13,14]. The sMV  clearly
ncreased the proportion of children seroprotected against measles.
mong HIV-uninfected children, a sharp rise in the antibody titer
as observed in the months immediately following sMV, and was
aintained among previous MV  non-responders. The observed
iter increase among children who were immune prior to sMV  was
ransient and declined by 9 months post-sMV. This corresponds
ith previous work showing that a boost from additional doses
f measles vaccine on measles antibody levels may  be relatively
hort-lived among children who had previously shown an immune
esponse to vaccination [15].
Among HIV-infected children, the sMV  led to a transient boost
n antibodies which waned rapidly over time, even in those who
ere not seroprotected pre-sMV. Neither the proportion seropro-
ected nor the GMC  was signiﬁcantly higher by 9 months post-sMV
han pre-sMV. Our ﬁndings were consistent with previous studies
hich demonstrate the rapid decline in vaccine-induced measles
ntibody titers and a lack of sustained response to MV in HIV-
nfected children [16]. The very small number of children who
eveloped HIV infection subsequent to primary measles vaccina-
ion maintained better measles positivity and seroprotective levels
f antibody compared with children who were HIV-infected at the
ime of primary vaccination. However, the measles antibody levels
or these late HIV seroconverters were diminished in comparison
ith HIV-uninfected children. A review of recent studies indicated
hat revaccination after immune reconstitution via antiretroviral
herapy can result in sustained immune responses to measles [17].The sMV  evaluation had limitations, since the original design
id not account for the SIA. As a result, the <3 months post-sMV
ime period established for early immune response evaluation con-
ained small numbers of children in each group. However, among4 (2016) 1459–1464 1463
HIV-uninfected child groups, subsequent time periods were well
powered for detection of differences. Due to high mortality and
dropout rates among HIV-infected children, our sMV  evaluations
included only small numbers of HIV-infected children. Finally, our
study was  conducted prior to routine use of antiretroviral medica-
tions and CD4 counts of the children were unavailable, precluding
an evaluation of their speciﬁc effects on MV  antibody responses.
For WHO  regions to achieve their goal for measles elimination
by 2020, an estimated population immunity of 93–95% must be
maintained. Our ﬁndings provide support for the WHO  measles
vaccine delivery strategy that provides an additional opportunity
for measles vaccination, and conﬁrm that the sMV  is safe and effec-
tive for children receiving either early, 2-dose or routine, 1-dose
MV.  Our ﬁndings further suggest that early MV  administration can
provide measles immunity to a substantial proportion of suscep-
tible young infants without interference of antibody responses to
subsequent MV  doses administered as part of SIAs.
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